FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3039690284> ?p ?o ?g. }

• W3039690284 endingPage "2673" @default.
• W3039690284 startingPage "2665" @default.
• W3039690284 abstract "Minimal residual disease (MRD) is the strongest predictor of relapse in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). In BLAST study (NCT01207388), adults with BCP-ALL in remission with MRD after chemotherapy received blinatumomab, a CD19 BiTE® immuno-oncotherapy, 15 µg/m2/day for up to four 6-week cycles (4 weeks continuous infusion, 2 weeks off). Survival was evaluated for 110 patients, including 74 who received HSCT in continuous complete remission. With a median follow-up of 59·8 months, median survival (months) was 36·5 (95% CI: 22.0–not reached [NR]). Median survival was NR (29.5–NR) for complete MRD responders (n = 84) and 14.4 (3.8–32.3) for MRD non-responders (n = 23; p = 0.002); after blinatumomab and HSCT, median survival was NR (25.7–NR) (n = 61) and 16.5 (1.1–NR) (n = 10; p = 0.065), respectively. This final analysis suggests complete MRD response during blinatumomab treatment is curative. Post-hoc analysis of study data suggests while post blinatumomab HSCT may be beneficial in appropriate patients, long-term survival without HSCT is also possible." @default.
• W3039690284 created "2020-07-10" @default.
• W3039690284 creator A5000436961 @default.
• W3039690284 creator A5011806164 @default.
• W3039690284 creator A5018514641 @default.
• W3039690284 creator A5020684790 @default.
• W3039690284 creator A5024202047 @default.
• W3039690284 creator A5026967725 @default.
• W3039690284 creator A5029898558 @default.
• W3039690284 creator A5041945240 @default.
• W3039690284 creator A5047060286 @default.
• W3039690284 creator A5067318724 @default.
• W3039690284 creator A5068237492 @default.
• W3039690284 creator A5070044155 @default.
• W3039690284 creator A5075073484 @default.
• W3039690284 creator A5077099095 @default.
• W3039690284 creator A5091739351 @default.
• W3039690284 date "2020-07-03" @default.
• W3039690284 modified "2023-10-18" @default.
• W3039690284 title "Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia" @default.
• W3039690284 cites W1485389706 @default.
• W3039690284 cites W1879221139 @default.
• W3039690284 cites W1967348190 @default.
• W3039690284 cites W1977380325 @default.
• W3039690284 cites W1991644988 @default.
• W3039690284 cites W1998660089 @default.
• W3039690284 cites W1999573477 @default.
• W3039690284 cites W2039642633 @default.
• W3039690284 cites W2049000194 @default.
• W3039690284 cites W2050152294 @default.
• W3039690284 cites W2058885398 @default.
• W3039690284 cites W2065079081 @default.
• W3039690284 cites W2069085828 @default.
• W3039690284 cites W2081127271 @default.
• W3039690284 cites W2109388187 @default.
• W3039690284 cites W2166295047 @default.
• W3039690284 cites W2525939690 @default.
• W3039690284 cites W2613210669 @default.
• W3039690284 cites W2783329475 @default.
• W3039690284 cites W2787145330 @default.
• W3039690284 cites W2900007121 @default.
• W3039690284 cites W2911504656 @default.
• W3039690284 cites W4237606124 @default.
• W3039690284 cites W4372230389 @default.
• W3039690284 doi "https://doi.org/10.1080/10428194.2020.1780583" @default.
• W3039690284 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32619115" @default.
• W3039690284 hasPublicationYear "2020" @default.
• W3039690284 type Work @default.
• W3039690284 sameAs 3039690284 @default.
• W3039690284 citedByCount "35" @default.
• W3039690284 countsByYear W30396902842020 @default.
• W3039690284 countsByYear W30396902842021 @default.
• W3039690284 countsByYear W30396902842022 @default.
• W3039690284 countsByYear W30396902842023 @default.
• W3039690284 crossrefType "journal-article" @default.
• W3039690284 hasAuthorship W3039690284A5000436961 @default.
• W3039690284 hasAuthorship W3039690284A5011806164 @default.
• W3039690284 hasAuthorship W3039690284A5018514641 @default.
• W3039690284 hasAuthorship W3039690284A5020684790 @default.
• W3039690284 hasAuthorship W3039690284A5024202047 @default.
• W3039690284 hasAuthorship W3039690284A5026967725 @default.
• W3039690284 hasAuthorship W3039690284A5029898558 @default.
• W3039690284 hasAuthorship W3039690284A5041945240 @default.
• W3039690284 hasAuthorship W3039690284A5047060286 @default.
• W3039690284 hasAuthorship W3039690284A5067318724 @default.
• W3039690284 hasAuthorship W3039690284A5068237492 @default.
• W3039690284 hasAuthorship W3039690284A5070044155 @default.
• W3039690284 hasAuthorship W3039690284A5075073484 @default.
• W3039690284 hasAuthorship W3039690284A5077099095 @default.
• W3039690284 hasAuthorship W3039690284A5091739351 @default.
• W3039690284 hasBestOaLocation W30396902841 @default.
• W3039690284 hasConcept C126322002 @default.
• W3039690284 hasConcept C143998085 @default.
• W3039690284 hasConcept C2776694085 @default.
• W3039690284 hasConcept C2777408962 @default.
• W3039690284 hasConcept C2778020697 @default.
• W3039690284 hasConcept C2778461978 @default.
• W3039690284 hasConcept C2779134260 @default.
• W3039690284 hasConcept C2779823535 @default.
• W3039690284 hasConcept C2781107101 @default.
• W3039690284 hasConcept C2909962599 @default.
• W3039690284 hasConcept C3018657049 @default.
• W3039690284 hasConcept C71924100 @default.
• W3039690284 hasConcept C90924648 @default.
• W3039690284 hasConceptScore W3039690284C126322002 @default.
• W3039690284 hasConceptScore W3039690284C143998085 @default.
• W3039690284 hasConceptScore W3039690284C2776694085 @default.
• W3039690284 hasConceptScore W3039690284C2777408962 @default.
• W3039690284 hasConceptScore W3039690284C2778020697 @default.
• W3039690284 hasConceptScore W3039690284C2778461978 @default.
• W3039690284 hasConceptScore W3039690284C2779134260 @default.
• W3039690284 hasConceptScore W3039690284C2779823535 @default.
• W3039690284 hasConceptScore W3039690284C2781107101 @default.
• W3039690284 hasConceptScore W3039690284C2909962599 @default.
• W3039690284 hasConceptScore W3039690284C3018657049 @default.
• W3039690284 hasConceptScore W3039690284C71924100 @default.
• W3039690284 hasConceptScore W3039690284C90924648 @default.
• W3039690284 hasFunder F4320307105 @default.

• next